BCL2L11 and acute lymphoblastic leukemia: However, the therapeutic approach of miR-26a needs to be carefully considered based on the fact that miR-26a has been found to be up-regulated in T-ALL patients and its expression enhanced leukemogenesis in a mouse model of T-ALL by suppressing the levels of PTEN and BIM tumor suppressor protein (77).